Stella Diagnostics (Stella Diagnostics) Net Margin % : 0.00% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Stella Diagnostics's Net Income for the three months ended in Sep. 2023 was $-0.82 Mil. Stella Diagnostics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Stella Diagnostics's net margin for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for Stella Diagnostics's Net Margin % or its related term are showing as below:

SLDX's Net Margin % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: -12.7
* Ranked among companies with meaningful Net Margin % only.

Stella Diagnostics Net Margin % Historical Data

The historical data trend for Stella Diagnostics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Net Margin % Chart

Stella Diagnostics Annual Data

Trend

Net Margin %

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Net Margin %	-	-

Competitive Comparison of Stella Diagnostics's Net Margin %

For the Diagnostics & Research subindustry, Stella Diagnostics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stella Diagnostics's Net Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Stella Diagnostics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Stella Diagnostics's Net Margin % falls into.

Stella Diagnostics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Stella Diagnostics's Net Margin for the fiscal year that ended in . 20 is calculated as

Net Margin	=	Net Income (A: . 20 )	/	Revenue (A: . 20 )
	=		/
	=	%

Stella Diagnostics's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin	=	Net Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-0.816	/	0
	=	%

Stella Diagnostics (OTCPK:SLDX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Stella Diagnostics Net Margin % Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.